SCHEMBL22465613

SCHEMBL22465613

CC(C)=CCc1c(O)cc2c(c1O)C(=O)CC(c1ccccc1O)O2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1H O95180 6/20 1.00
SOAT2 O75908 2/20 0.73
CACNA1G O43497 1/20 0.72
ESR1 P03372 1/20 0.72
MAPT P10636 1/20 0.72
MAPK1 P28482 1/20 0.72
KMT2A Q03164 1/20 0.72
ATM Q13315 1/20 0.72
NPSR1 Q6W5P4 1/20 0.72
PLA2G1B P04054 1/20 0.69
PTPN1 P18031 3/20 0.68
SOAT1 P35610 1/20 0.64
PTPN12 Q05209 1/20 0.64
PTPN22 Q9Y2R2 1/20 0.64
ACHE P22303 2/20 0.61
PTGS2 P35354 2/20 0.61
TP53 P04637 1/20 0.61
MDM2 Q00987 1/20 0.61
ELANE P08246 1/20 0.60
ALOX5 P09917 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22465348 0.90 CACNA1H (1.00) CACNA1HSOAT2CACNA1GESR1MAPT
Cudraflavanone B SCHEMBL23140484 0.88 CACNA1H (0.79) CACNA1HSOAT2CACNA1GESR1MAPT
SCHEMBL22465767 0.88 CACNA1H (0.79) CACNA1HSOAT2CACNA1GESR1MAPT
SCHEMBL1171132 0.88 CACNA1H (0.84) CACNA1HSOAT2CACNA1GESR1MAPT
SCHEMBL24075694 0.88 CACNA1H (0.84) CACNA1HSOAT2CACNA1GESR1MAPT
SCHEMBL22465747 0.87 CACNA1H (0.77) CACNA1HSOAT2CACNA1GESR1MAPT
SCHEMBL145714 0.84 CACNA1H (1.00) CACNA1HSOAT2CACNA1GESR1MAPT
SCHEMBL22465607 0.84 CACNA1H (1.00) CACNA1HSOAT2CACNA1GESR1MAPT
SCHEMBL145713 0.84 CACNA1H (1.00) CACNA1HSOAT2CACNA1GESR1MAPT
SCHEMBL29394512 0.84 CACNA1H (1.00) CACNA1HSOAT2CACNA1GESR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479537-B2 T-type calcium channel inhibitor KINKI UNIVERSITY (JP) 2022-10-25 US claimed
US-20200308132-A1 T-TYPE CALCIUM CHANNEL INHIBITOR NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) 2020-10-01 US claimed
US-11479537-B2 T-type calcium channel inhibitor KINKI UNIVERSITY (JP) 2022-10-25 US disclosed
US-20200308132-A1 T-TYPE CALCIUM CHANNEL INHIBITOR NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (JP) 2020-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11479537-B2 T-type calcium channel inhibitor CACNA1H, CACNA1I, CACNA1G CACNA1H 1/4885SOAT2 2503/4885CACNA1G 3/4885
US-20200308132-A1 T-TYPE CALCIUM CHANNEL INHIBITOR CACNA1H, CACNA1I, CACNA1G CACNA1H 1/4885SOAT2 2503/4885CACNA1G 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.